BRICANYL
LOE ApproachingNDAORALTABLET
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is an oral small-molecule tablet approved in 1975 by Sanofi; generic composition and mechanism of action are not specified in available data. The drug is approaching loss of exclusivity, indicating a mature asset nearing patent cliff.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the commercial team is likely focused on retention and margin optimization rather than market expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
Working on BRICANYL represents a high-risk, low-growth assignment focused on defensive brand management and revenue protection during LOE transition. Career value depends on ability to lead cost optimization and generic launch strategy rather than innovative product development.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.